SA Analyst flags rising war risks and oil spike as catalysts for broader market weaknessMarch 30, 2026
Share Facebook Twitter LinkedIn Pinterest Email Biogen receives FDA approval for high-dose Spinraza regimen
SA Analyst flags rising war risks and oil spike as catalysts for broader market weaknessMarch 30, 2026